Are you looking for new additions to your investment portfolio this week?
If you are, it could be a good idea to check out the ASX 200 tech shares listed below that Morgans is urging clients to accumulate. Here's what the broker is saying about them:
Image source: Getty Images
Pro Medicus Ltd (ASX: PME)
This health imaging technology company could be worth accumulating according to the broker.
Following recent share price weakness, the broker has seen an opportunity for investors to build a position in this quality stock. It said:
PME's share price has continued to decline since our last update, despite stable fundamentals and a consistent outlook. This decrease appears to be due to a broader market shift away from high-growth stocks, as there have been no major new contracts or company-specific changes for PME since our previous report. Business quality remains solid with high margins, long-term contracted revenues, and a growing contract book which underpins the demand and safety in the financial profile over the coming years.
Morgans upgraded Pro Medicus' shares to an accumulate rating with a $290.00 price target. The broker adds:
No change to valuation (A$290 p/s) and longstanding positive outlook, just a better entry point. Upgrade to an ACCUMULATE recommendation, with the view that current prices represent a reasonable opportunity for partial positions, noting ongoing volatility in the name could still yet present further downside.
REA Group Ltd (ASX: REA)
Another ASX 200 tech share that has been upgraded to an accumulate rating (with a $247 price target) is property listings company REA Group.
The broker was pleased with its first quarter update and sees value in its shares at current levels. It said:
REA's 1Q26 trading update benefited from a strong yield outcome (+13%), which helped to offset a softer new listings environment in the period (volumes down -8% vs the pcp). Group revenue was A$429m (+4% on pcp), with EBITDA (ex assoc.) up 5% on pcp to A$254m. We make minor changes (-1%) to our FY26-FY28 EPS estimates. Our DCF-derived price target is lowered to A$247 (from A$254). Given REA is trading on ~42x FY26F PE (MorgansE), broadly in line with its 10-year historical average, and now with >10% TSR upside to our valuation we upgrade REA to ACCUMULATE.
Xero Ltd (ASX: XRO)
A third ASX 200 tech share that has caught the eye of analysts at Morgans is Xero. It has put an accumulate rating and $141 price target on its shares.
The broker would be more positive on the cloud accounting platform provider but concedes that it may take some time for the market to become confident in the acquisition of Melio. It said:
XRO's 1H26 result was largely in line with expectations but higher investment expenses in the 2H and the inclusion of Melio into our forecasts lowers our EBITDA and FCF forecasts. Our prior XRO research presented our first take on XRO including Melio numbers and now, following its 1H26 result and greater clarity on costs, we reduce our short-term forecasts and formally publish our combined XRO and Melio forecasts.
Our target price reduces ~30% to $141 on lower peer multiples and lower FCF per share. We retain our Accumulate recommendation, noting it may take some time for management to build investor confidence in the value add of Melio and return XRO back to rule of 40 growth.
